drug_prior_trial_positve.pct
drug_prior_trial_count_norm_by_year
indication_prior_trial_count
indicationgrp_prior_trial_count
intpriorapproval
indication_prior_trial_positve.pct
hopeful
intsponsorid_p3_completed.pct_intclinicaltrialids_norm_by_year
indicationgrp_prior_trial_positve.pct
YEAR
intsponsorid_p2_completed.pct_intclinicaltrialids_rank_norm_by_year
intsponsorid_p2_positive.pct_intclinicaltrialids_rank_norm_by_year
age_range
intsponsorid_p1_negative_intclinicaltrialids_rank_norm_by_year
intsponsorid_p3_positive.pct_intclinicaltrialids_norm_by_year
intsponsorid_total_drugkey_indicationkey_rank_norm_by_year
indicationgrp_key_12_Anticancer
intsponsorid_p1_completed.pct_intclinicaltrialids_rank_norm_by_year
decmaxage
intpersonid_failure_drugkey_indicationkey
accrual_pct_rank_norm_by_year
intpersonid_p1_positive.pct_intclinicaltrialids_rank_norm_by_year
intsponsorid_failure_drugkey_indicationkey
intidentifiedsites_norm_by_year
intactualaccrual
intsponsorid_p3_terminated_intclinicaltrialids_rank_norm_by_year
decminage
intsponsorid_p1_positive.pct_intclinicaltrialids_rank_norm_by_year
intsponsorid_p3_positive_intclinicaltrialids
intduration
intsponsorid_p2_positive_intclinicaltrialids_norm_by_year
indicationgrp_key_14_Neurological
intpersonid_p3_completed_intclinicaltrialids_norm_by_year
intsponsorid_p3_completed_intclinicaltrialids_rank_norm_by_year
intsponsorid_p1_completed_intclinicaltrialids
intpersonid_postive.pct_drugkey_indicationkey
intsponsorid_postive.pct_drugkey_indicationkey
intsponsorid_p2_progress.pct_intclinicaltrialids_rank_norm_by_year
intpersonid_p2_completed.pct_intclinicaltrialids_rank_norm_by_year
intsponsorid_p1_progress.pct_intclinicaltrialids_rank_norm_by_year
intsponsorid_p3_progress.pct_intclinicaltrialids_rank_norm_by_year
intpersonid_total_drugkey_indicationkey_rank_norm_by_year
intpersonid_p2_progress.pct_intclinicaltrialids_norm_by_year
intpersonid_p2_positive.pct_intclinicaltrialids
intsponsorid_p2_negative_intclinicaltrialids_rank_norm_by_year
intpersonid_p1_completed.pct_intclinicaltrialids_norm_by_year
intsponsorid_p2_completed_intclinicaltrialids_norm_by_year
inttargetaccrual
indicationgrp_key_17_Sensory
intpersonid_p2_positive_intclinicaltrialids_rank_norm_by_year
intsponsorid_approval_drugkey_indicationkey_norm_by_year
intpersonid_p3_completed.pct_intclinicaltrialids_rank_norm_by_year
intpersonid_p3_positive.pct_intclinicaltrialids
intsponsorid_p1_positive_intclinicaltrialids_norm_by_year
indicationgrp_key_11_Anti
intpersonid_p3_progress.pct_intclinicaltrialids_norm_by_year
intpersonid_p1_negative_intclinicaltrialids_rank_norm_by_year
intpersonid_p1_progress.pct_intclinicaltrialids_rank_norm_by_year
indicationgrp_key_10_Immunological
indicationgrp_key_13_Musculoskeletal
intpersonid_p3_terminated_intclinicaltrialids_rank_norm_by_year
indicationgrp_key_16_Respiratory
intpersonid_p2_negative_intclinicaltrialids_rank_norm_by_year
intpersonid_p1_positive_intclinicaltrialids_rank_norm_by_year
indicationgrp_key_3_Alimentary
intpersonid_p3_positive_intclinicaltrialids_rank_norm_by_year
indicationgrp_key_4_Blood
indicationgrp_key_6_Dermatological
sponsor_class
indicationgrp_key_5_Cardiovascular
indicationgrp_key_9_Hormonal
indicationgrp_key_8_Genitourinary
indicationgrp_key_15_Antiparasitic
for_baby
for_elder
mediumdescription:
strterminationreason:terminated
strterminationreason: negative outcome/primary endpoints not met
drugdeliveryroutedescription: swallowed
mediumdescription:solution
strlocation:japan
strdesignkeyword:placebo control
therapydescription:anticancer
strsponsortype: all other pharma
strterminationreason: positive outcome/primary endpoints met
therapydescription:antisense therapy
strterminationreason:
drugtarget:protein phosphatase 1
therapydescription:reformulation
drugtarget: gamma
therapydescription: other
mediumdescription:tablet
strterminationreason: business decision - pipeline reprioritization
mediumdescription:suspension
strmechanismofaction:insulin sensitizer
drugdeliveryroutedescription:
strdesignkeyword:efficacy
strsponsortype: top 20 pharma
strdesignkeyword:pharmacokinetics
strdesignkeyword:randomized
strdesignkeyword:dose response
strdesignkeyword:safety
mediumdescription:capsule
therapydescription: modified-release
strlocation:united states
strdesignkeyword:
drugtarget: group c
drugtarget: member 2
strtherapeuticarea:metabolic/endocrinology
strtherapeuticarea:infectious disease
strmechanismofaction:
strtherapeuticarea:autoimmune/inflammation
drugdeliveryroutedescription:oral
therapydescription:antidepressant
strdesignkeyword:open label
therapydescription:monoclonal antibody
strlocation:germany
strlocation:italy
mediumdescription: hard
strtherapeuticarea:oncology
strlocation:france
strmechanismofaction:vaccine
therapydescription:dermatological
therapydescription:antidiabetic
strdesignkeyword:double blind/blinded
strdesignkeyword:multiple arm
therapydescription: fixed-dose combinations
drugtarget:d2 dopamine receptor
strregulatorystatus:
strlocation:china
therapydescription: antimetabolite
strtherapeuticarea:cns
drugtarget:polymerase
strmechanismofaction:insulin secretagogue
mediumdescription:powder
therapydescription: hormonal
therapydescription:antihypertensive
strpatientsegment:second line
drugtarget:not applicable
strmechanismofaction:monoclonal antibody
strterminationreason: outcome indeterminate
strtherapeuticarea:cardiovascular
therapydescription:symptomatic antidiabetic
therapydescription: inhalable
therapydescription:antiasthma
therapydescription:musculoskeletal
strlocation:ukraine
strdiseasetype:type 2 diabetes
drugdeliveryroutedescription:injectable
strdiseasetype:ovarian
strpatientsegment:mild
therapydescription:antiviral
strsponsortype:academic
strlocation:united kingdom
strdesignkeyword:active comparator
drugtarget: receptor
therapydescription:neuroprotective
strpatientsegment:moderate
strpatientsegment:n/a
therapydescription:prophylactic vaccine
strtherapeuticarea:genitourinary
strlocation:netherlands
therapydescription:antineurotic
strregulatorystatus:biomarker/efficacy
therapydescription: lessorequal24hr
drugtarget:avian erythroblastic leukemia viral v-erb-b oncogene homologue
therapydescription:antipsychotic
strpatientsegment:diet/exercise controlled
strpatientsegment:peripheral t-cell lymphoma ptcl
therapydescription:antiarthritic
strsponsortype:government
strdiseasetype:respiratory infections
therapydescription:copd treatment
drugdeliveryroutedescription: subcutaneous
therapydescription:analgesic
strpatientsegment:adults
strterminationreason:completed
drugtarget:opioid receptor
strpatientsegment:stage iii
strdiseasetype:leukemia
strdiseasetype:allergic rhinitis
drugtarget:unspecified
therapydescription:ophthalmological
strlocation:belgium
strmechanismofaction:immunostimulant
drugtarget:beta 1-tubulin
drugtarget: member 1 glucocorticoid receptor
therapydescription:antiepileptic
therapydescription: immunological
drugtarget:b-lymphocyte cell surface antigen b1
therapydescription:urological
strdiseasetype:multiple sclerosis
mediumdescription: soft
drugtarget:platelet-derived growth factor receptor
strdiseasetype:hypertension
strlocation:canada
therapydescription:bronchodilator
strpatientsegment:stage iv
strdiseasetype: non-hodgkin's
therapydescription: human
therapydescription:antianaemic
strsponsortype:industry
strmechanismofaction:therapeutic vaccine
therapydescription:anti-inflammatory
strpatientsegment:first line
therapydescription:multiple sclerosis treatment
therapydescription:gi inflammatory/bowel disorders
strlocation:austria
strlocation:russia
strlocation:norway
therapydescription:muscle relaxant
strpatientsegment:line of therapy n/a
therapydescription:cardiostimulant
therapydescription:fusion protein
strlocation:spain
drugdeliveryroutedescription:inhaled
strmechanismofaction:prophylactic vaccine
therapydescription:neurological
strdesignkeyword:cross over
strpatientsegment:treatment naive
therapydescription:antiparkinsonian
therapydescription:immunosuppressant
therapydescription:prostate disorders
strdesignkeyword:single arm
strdesignkeyword:pharmacodynamics
therapydescription: humanized
strpatientsegment:relapsing remitting rr
strmechanismofaction:protein kinase inhibitor
strdesignkeyword:immunogenicity
mediumdescription:cream
drugtarget:adrenergic
strtherapeuticarea:vaccines infectious disease
drugtarget:mgc70609
strmechanismofaction:dna antagonist
strpatientsegment:aggressive
strdiseasetype:hiv
strpatientsegment:stage i
strdiseasetype:acute coronary syndromes
strdiseasetype:lung
strdiseasetype:overactive bladder
strlocation:czech republic
strdiseasetype:n/a
therapydescription: antiglaucoma
drugdeliveryroutedescription: intravenous
strlocation:australia
strpatientsegment:fourth line or greater
strlocation:south africa
strpatientsegment:severe
strdesignkeyword:fixed dose
therapydescription: non-asthma
strpatientsegment:patients only on metformin
drugtarget: large subunit
therapydescription:anxiolytic
strlocation:denmark
therapydescription: systemic
therapydescription:cognition enhancer
drugtarget: hiv-1
strmechanismofaction:apoptosis stimulant
therapydescription:antithrombotic
strlocation:poland
therapydescription:antipsoriasis
strpatientsegment:seasonal allergic rhinitis sar
drugtarget: bcr fusion-linked
strpatientsegment:remission
therapydescription: anti-hiv
strlocation:south korea
therapydescription:cardiovascular
drugtarget:protease
therapydescription:osteoporosis treatment
therapydescription: oral
therapydescription:respiratory
strmechanismofaction:cell cycle inhibitor
drugtarget: g-protein-coupled
strpatientsegment:stage ii
strmechanismofaction:platelet-derived growth factor pdgf receptor tyrosine kinase inhibitor
